unknown by unknown
cell culture conditions (ie MET+HCY- [the symbols + and ￿ denote the 
presence or absence of supplements in the media respectively]), HTC cells 
grew with a doubling time of 20 h in the exponential phase. In MET-HCY+ 
media, no cell growth occurred and cells accumulated in the S/G2 phase of 
the cell cycle. The cells remained viable during the period of MET 
deprivation as replacement of MET-HCY+ media with MET+HCY-media 
(after 5 and 10 days of MET-HCY+ treatment) resulted in cell proliferation 
and a normalisation of cell cycle parameters 3 to 4 days later. Both Phi-1 and 
Hs-27 cells (MET independent) were able to grow in MET-HCY+ media 
albeit at a reduced rate compared with cells in MET+HCY- media (doubling 
time for Hs-27 cells in MET+HCY- or MET-HCY+ media were 24 and 72 h 
respectively). Under MET-HCY+ conditions, no significant changes in cell 
cycle parameters were observed for Phi-1 and Hs-27 cells compared with 
parameters obtained in MET+HCY- media. This study suggests that the 
differences that exist between tumour and normal cells in terms of their MET 
dependence may provide a novel biochemical strategy by which MET 
dependent cells could be synchronised into specific phases of the cell cycle. 
As the cell cycle parameters of MET independent cells (ie normal cells) are 
not altered under MET deprived conditions, the appropriate use of cell cycle 
phase specific agents may therefore improve the therapeutic index of both 
standard chemotherapeutic agents and novel therapeutic agents. This work 
was supported by Cancer Research UK. 
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PROTEIN DEGRADATION IN SKELETAL MUSCLE IS INDUCED 
BY A PROTEOLYSIS INDUCING FACTOR (PIF) AND IS 
ASSOCIATED WITH INCREASED EXPRESSION OF MEMBERS OF 
THE UBIQUITIN-PROTEASOME PATHWAY PROTEOLYSIS-
INDUCING FACTOR (PIF) AND WITH THE ACTIVATION OF THE 
TRANSCRIPTION FACTOR NFκκκκ B.
AS Whitehouse* and MJ Tisdale,  Pharmaceutical Sciences Research 
Institute, Aston University, Birmingham, B4 7ET, UK 
Proteolysis Inducing Factor (PIF), isolated from a cachexia-inducing murine 
tumour, has been shown to stimulate protein catabolism in C2C12 myotubes.  
Protein degradation was enhanced by PIF after 24hours, which corresponded 
with an elevation in the chymotrypsin-like enzyme activity of the proteasome 
(the dominant catalytic activity of the β -subunits) and expression of 20Sα  -
subunits at concentrations of PIF between 2 and 16nM.   Higher 
concentrations of PIF had no effect. A similar pattern was seen for expression 
of subunits of the 19S regulatory particle and E214k (the ubiquitin conjugating 
enzyme). The action of PIF was attenuated by the polyunsaturated fatty acid - 
eicosapentaenoic acid (EPA) (50￿M).  At a concentration of 4nM, PIF 
induced a transient decrease in Iκ Bα  levels after 30min incubation, while no 
effect was seen at 40nM PIF.  The level of Iκ Bα , an NFκ B inhibitory protein, 
returned to normal after 60min.  Depletion of Iκ Bα  fr! om the cytosol was 
not seen in myotubes pre-treated with EPA, suggesting that the NFκ B / Iκ B
complex was stabilised.  At concentration of 2 and 8nM, PIF stimulated an 
increased nuclear migration of NFκ B, which was not seen in myotubes pre-
treated with EPA   The PIF-induced increase in chymotrypsin-like enzyme 
activity was attenuated by the NFkB inhibitor peptide -SN50, suggesting that 
NFκ B may be involved in the PIF-induced increase in proteasome 
expression.  The results further suggest that PIF co-ordinately upregulates 
expression of members of the ubiquitin -proteasome proteolytic pathway and 
that EPA may attenuate protein catabolism, at least partly, by preventing 
NFκ B accumulation in the nucleus. 
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QUANTITATIVE ANALYSIS OF THE AH RECEPTOR 
SIGNALLING PATHWAY.  
Morag C.E. McFadyen
*, Patrick H Rooney, Graeme I. Murray. Department 
of Pathology, University of Aberdeen, Aberdeen, AB25 2ZD UK. 
The aryl hydrocarbon receptor (AhR) is a ligand activated receptor which on 
dimerisation with the aryl hydrocarbon nuclear translocator (ARNT) binds to 
xenobiotic responsive elements (XREs) that promotes the activation of a 
battery of genes, including the cytochrome P450 drug metabolising enzymes 
CYP1A1 and CYP1B1.  These two P450s are known to demonstrate distinct 
cell type expression. Indeed, we have previously shown that CYP1B1 is a 
tumour-specific P450
1 and recently established several anti-cancer drugs as 
substrates for CYP1B1
2.  The aim of this study was to investigate the 
mechanism of cellular regulation of CYP1A1 and CYP1B1 by real time 
quantitative RT-PCR in three cell lines (MCF7, HEPG2 and MOG-G-CCM) 
known to differentially express CYP1A1 and CYP1B1 mRNA.  In this 
investigation basal and inducible levels of CYP1A1 and CYP1B1 mRNA 
were determined for the three cell lines.  The cells were exposed to the Ah 
receptor agonist 3-methylcholanthrene (3-MC) for a 12hr time period to 
determine the levels of inducible CYP1A1 and CYP1B1 mRNA.  Specific 
primers and fluorescently labelled probes were designed for each cDNA, 
quantification of the mRNA was determined by the ABI7700 sequence 
detection system.  Detection of the AhR and ARNT transcripts demonstrated 
basal levels for each amplicon, minimal changes in expression levels was 
observed on exposure to 3-MC.  However, our results demonstrated 
differential basal and inducible expression of CYP1A1 and CYP1B1 in the 
cell lines.  CYP1A1 basal expression was 3 and 5 fold higher in the HEPG2 
cells compared to the MCF7 and MOG-G-CCM cells respectively.  Where as 
basal CYP1B1 expression in the MCF7 and MOG-G- CCM cells was 500 
and 4,000 fold higher than in the HEPG2 cells respectively.  On exposure to 
3-MC both CYP1A1 and CYP1B1 mRNA levels increased in all three cell 
lines.  However the level of CYP1A1 mRNA in the MOG-G-CCM and 
CYP1B1 mRNA in the HEPG2 cell line exposed to 3-MC was below the 
threshold level for basal expression of the transcripts observed in the other 
two cell lines.  Following exposure to 3-MC; MCF7 cells show inducible 
expression of both CYP1A1 and CYP1B1 protein, HEPG2 cells express 
CYP1A1 protein and MOG-G-CCM cells CYP1B1 protein.  The results of 
this study suggest that a threshold of expression for CYP1A1 and CYP1B1 
mRNA expression must be obtained before expression of protein occurs.   
This may indicate why although CYP1B1 mRNA is present in normal tissue 
the protein is not detectable. 
References 
1. Murray GI, Melvin WT, Greenlee WF, Burke MD. 2001 Annu Rev 
Pharmacol Toxicol 41: 297. 
2. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. 2001 J 
Pharmacol Exp Ther 296: 537. 
Acknowledgement: Research was funded by University of Aberdeen 
Development Trust. 
P166 
CONJUGATED LINOLEIC ACID ENRICHED MILKFATS INHIBIT 
GROWTH AND MODULATE PROSTAGLANDIN PRODUCTION IN 
THE MCF-7 HUMAN CANCER CELL LINE.  
A. Miller*, C. Stanton
1, J. Murphy
2and R. Devery. 
School of Biotechnology, National Institute for Cellular Biotechnology, 
Dublin City University, Dublin 9, Ireland; 
1Teagasc Dairy Products Research 
Centre, Moorepark, Fermoy, Co. Cork, Ireland; 
2Teagasc, Dairy Production 
Department, Moorepark, Fermoy, Co. Cork, Ireland.  
Because of the potential health benefits attributed to CLA, strategies for CLA 
enrichment of milkfat have been identified with a view to production of 
CLA-enriched functional foods. Milk enriched in CLA was obtained from 
cows on pasture supplemented with full fat rapeseeds (FFR) and full fat 
soyabeans (FFS). Control milkfat was obtained from cows on pasture only. In 
this study, we  compared the potency of the CLA-enriched milkfats with 
control milkfat to influence growth, eicosanoid production, lipid peroxidation 
and glutathione levels in human MCF-7 breast cancer cells. Cell numbers, as 
measured by trypan blue exclusion, decreased (by 48-66 %) following 
incubation of MCF-7 cells for 4 days with the three different milkfats (added 
at 1mg/ml) yielding CLA concentrations between 16.9 and 22.6 µ g/ml. When 
the three milkfats were added at different concentrations, to yield a final CLA 
concentration of 20 µ g/ml, significantly (p<0.05) lower cell numbers were 
obtained (42-44 % of control), confirming the anticarcinogenic potency of 
milkfat CLA. Vaccenic acid, a milk fatty acid  may also influence MCF-7 
cell growth.  When incubated with MCF-7 cells at the concentrations present 
in the milkfats (31.4 - 46.4 µ g/ml) significant (p<0.05) decreases in cell 
growth were observed . Only the FFR milk fat (containing 22.6 µ g/ml CLA) 
significantly (p<0.05) altered prostaglandin synthesis at 24h, increasing 
PGF2α  (by 29 %) and decreasing PGE2 (by 22 %).  None of the milkfats 
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PGF2α  increased (p<0.05) by 55-92 % following incubation with the three 
milkfats. All milkfats significantly decreased (p<0.05) glutathione levels by 
17-38 % in cytosolic extracts. Lipid peroxidation and depletion in glutathione 
levels are indicative of a signalling pathway initiating apoptosis. The data  
suggest that apoptosis may be the mode of cell death induced by the CLA-
enriched milkfats in the MCF-7 cancer cell line.  
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A NEW APPROACH TO BREAST CANCER CONTROL.   TURNING 
CELL CYCLE CONTROLLER GENES INTO CANCER DRUGS 
Valerie Wells* and Livio Mallucci  
Cell Signalling and Growth Laboratory, Division of Life Sciences, King￿s 
College London, 150 Stamford Street, London SE1 9NN. 
Breast cancer is a widespread disease. Like many other cancers, cancers of 
the breast can be refractory to chemotherapy which may instead remain 
harmful to normal cells, including those of the immune system and 
progenitor cells. Our strategy is based on the use of a naturally occurring 
immunomolecule with a putative role in cancer surveillance, based on its 
ability to exploit genetic differences between normal and cancer cells. The 
betaGBP cytokine
1 negatively regulates the cell cycle by activating an S 
phase checkpoint. Downregulation of tyrosine kinase receptor activated 
signalling by betaGBP results in altered expression of cell cycle controller 
genes which in cancer cells, but not in normal cells, activate programmed cell 
death. In particular the E2F-1 transcription factor has emerged as a key player 
in promoting apoptosis. Our studies are focused on mammary cancer cells
2
which differ in oestrogen receptors status, expression of the EGF family of 
receptors and sensitivity to chemotherapeutic drugs. For the present 
investigation we have selected the following breast cancer cell lines: BT20, 
T47D, MCF7 and MCF7-D40 (doxorubicin resistant). MCF10a, a line of 
normal luminal breast cells is used as a comparison. We have found that all 
the cancer cells, including the drug resistant ones, but not the normal breast 
luminal cells initiate a death programme after a gap period of 2-5 days from 
betaGBP enforced S/G2 arrest. We have evidenced two stages in the response 
to treatment with betaGBP: Stage 1, growth arrest; stage 2, after a varying 
time-lag,  apoptosis. We are examining which genes are responsible for stage 
1 and stage 2 responses. Genes involved in stage 1 include those controlling 
the expression of PI3-kinase signalling and Ras-MAP kinase signalling. 
Genes involved in stage 2 include those involved in cyclin kinase activity and 
E2F-1 expression, a gene highly expressed in cancer cells, whose 
deregulation leads to E2F-1 induced apoptosis. We are manipulating the 
expression of these genes to identify critical steps in the chain of events 
activated by betaGBP which may be selected as direct targets in drug 
development. 
1 Blaser, C., Kaufmann, M., Muller, C., Zimmerman, C., Nath, N., Mallucci, 
L. and Pircher, H. (1998). beta-Galactoside-binding  protein secreted by 
activated T cells inhibits antigen-induced proliferation of T cells.  European 
Journal of Immunology 28, 2311. 
2 Wells, V., Davies, D., and Mallucci, L. (1999). Cell cycle arrest and 
induction of apoptosis by beta-galactoside binding protein in human 
mammary cancer cells. A potential new approach to cancer control.   
European Journal of Cancer 35, 978. 
This work is supported by the Breast Cancer Campaign. 
P168 
TIP60 CORRELATES WITH THE DIFFERENTIATED PHENOTYPE 
IN LNCaP PROSTATE CANCER CELLS 
K Halkidou*, S Cook, ME Brady, DE Neal, CN Robson;  
Prostate Research Group, Dept. of Surgery, University of Newcastle Medical 
School, Newcastle-Upon-Tyne, NE2 4HH 
Prostate cancer (CaP) is the second most prevalent malignancy in UK men, 
accounting for more than 10,000 deaths each year. Prostatic tumours are 
initially androgen-sensitive and regress after androgen ablation. However, 
most disseminated and highly de-differentiated prostate adenocarcinomas 
eventually recur, at which point they are termed ￿androgen refractory￿, and 
can no longer be cured by current conventional therapy. We have previously 
identified Tip60 as a coactivator of the human androgen receptor (AR). We 
have also shown that nuclear localization of Tip60 inversely correlates with 
metastasis at the time of diagnosis. The direct link between loss of the 
differentiated phenotype and the degree of malignancy of the tumour, 
highlights the importance of studying factors associated with differentiation. 
Since cellular differentiation is largely a matter of transcriptional regulation, 
we were intrigued to examine Tip60￿s involvement in the process of prostate 
epithelium differentiation.  
MATERIALS AND METHODS: Western blotting was performed to 
examine the protein levels of several cell cycle regulatory molecules and 
differentiation markers in prostate cancer LNCaP cells treated with 
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor. 
Immunofluorescence staining was also undertaken for those samples. Flow 
cytometry analysis of Tip60 expression levels and cell cycle profile analysis 
were performed. Growth assays were also used to demonstrate TSA￿s effect 
on cell proliferation. RESULTS: TSA causes growth arrest and 
differentiation in LNCaP cells, an androgen responsive CaP cell line. We 
observed a downregulation of cyclin D1 and an upregulation of p21 in 
response to TSA treatment. Cell cycle analysis showed TSA arrested LNCaP 
cells both at G2/M and G1. Immunofluorescence staining of cytokeratin 18 
demonstrated a reorganization of the cytoskeleton upon TSA treatment, 
together with upregulation and predominantly nuclear expression of Tip60, in 
a distinct speckled pattern.  At the same time, histone 4 hyperacetylation 
directly correlated with the differentiated phenotype. Co-expression of Tip60 
with low molecular weight cytokeratins in primary cultures of normal 
epithelial prostate cells also indicated a connection between Tip60 and the 
secretory phenotype in benign prostate cells.CONCLUSIONS: Our results 
indicate that Tip60 may be involved in the differentiation process, as it is 
upregulated and localizes in the nucleus in LNCaP cells caused to 
differentiate by TSA treatment. Our hypothesis is that Tip60, a histone 
acetyltransferase enzyme and AR co-activator, plays an important role in the 
differentiation course in prostate epithelium, possibly by enhancing AR 
transactivation in response to differentiating stimuli. This role may be altered 
as the disease progresses towards the androgen independent status. 
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BRCA1 MEDIATED CELL APOPTOSIS IN RESPONSE TO TAXOL 
Quinn J.E *, Gilmore PG, McCabe N, Mullan PB, Andrews H, Johnston PG, 
Harkin DP and Kennedy RD. Oncology Department, Queen￿s University 
Cancer Research Centre, Belfast City Hospital, Lisburn Road, Belfast, 
N.Ireland, BT9 7AB. 
BRCA1 is a tumour suppressor gene implicated in the predisposition to early 
onset breast and ovarian cancer. In our previous work (Mullan and Quinn et
al., Oncogene, 2001, 20, 6123-6131), we generated cell lines with inducible 
expression of BRCA1 to evaluate its role in mediating the cellular response 
to various chemotherapeutic drugs commonly used in the treatment of breast 
and ovarian cancer. We observed a dramatic interaction between BRCA1 
induction and exposure to the antimicrotubule agent, Taxol that functions by 
inhibiting the depolymerization of tubulin. Induction of BRCA1 in the 
presence of Taxol resulted in a complete loss of cell viability, an effect that 
was preceded by a transient arrest at the G2/M phase of the cell cycle and 
which correlated with BRCA1 mediated induction of GADD45. A proportion 
of the arrested cells were blocked in mitosis suggesting the involvement of 
BRCA1 in the activation of both a G2 and a mitotic spindle checkpoint. 
Our current focus is to investigate the mechanism of BRCA1 mediated cell 
death in response to Taxol. We have demonstrated by parp and caspase 
cleavage assays that this is an apoptotic mechanism and have preliminary 
evidence to suggest that the mechanism may involve either the JNK kinase 
and/or p38 apoptotic pathways. We aim to provide further evidence that 
BRCA1 can mediate the cytotoxic effects of antimicrotubule agents through 
activation of the JNK or p38/MAPK pathways. In order to do this we have 
generated cells that express both inducible BRCA1 and dominant negative 
MEKK3, the common upstream regulator of both JNK and p38. We aim to 
use these cells to determine if abrogation of these pathways can prevent 
BRCA1 mediated cell death in response to Taxol. Finally, our data suggests 
that BRCA1 expression levels in tumours may be an important determinant 
of response to these compounds.  
REFERENCE 
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to 
antimicrotubule agents. Mullan PB, Quinn JE, Gilmore PM, Mc Williams S, 
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ACTIVATION OF THE PROTEASOME AND APOPTOTIC 
PATHWAYS BY A CACHECTIC FACTOR AND ATTENUATION BY 
ICOSAPENTAENOIC ACID 
H J Smith* and M J Tisdale, Pharmaceutical Sciences Research Institute, 
Aston University, Aston Triangle, Birmingham, B4 7ET. 
A proteolysis inducing factor (PIF) was isolated from a cachexia - inducing 
murine tumour (MAC16). The effect on protein degradation through the 
ubiquitin-proteasome proteolytic pathway as well as the induction of 
apoptosis in skeletal muscle was determined using C2C12 myotubes as a 
surrogate model. Proteasome activity was assessed using chymotrypsin 
activity, and was increased by PIF at 4.2nM (p<0.005) after 24h incubation. 
The expression of alpha and beta subunits of the proteasome 20S core, along 
with the conjugating enzyme E2, were shown to be increased by Western 
Blotting of myotube supernatants at a concentration of PIF  between 1 and 
20nM. This increase in proteasome activity and expression was attenuated by 
50µ M EPA. 
The activity of cysteinyl - directed aspartate specific proteases was also 
measured fluorometrically in C2C12 myotubes. PIF was shown to stimulate 
the apoptotic initiating caspases 8 and 9 at 2.1 and 4.2nM (p<0.01), and the 
apoptotic effectors caspases 2, 3 and 6 also at 2.1 and 4.2nM (p<0.001). The 
activation of these caspases was inhibited by 50µ M EPA. Western Blotting 
analysis showed that PIF induced an increased expression of caspase 3, the 
apoptotic protein Bax and cytochrome c between 1 and 20nM in C2C12 
myotubes, an effect that was again attenuated by 50µ M EPA. A non-isotopic 
assay for the quantitation of free nucleasomes in apoptotic cells showed that 
PIF significantly increased the formation of apoptotic nucleasomes between 1 
and 20nM  (p<0.05) in C2C12 myotubes. 
These results suggest PIF increases proteasome activity and induces apoptotic 
pathways in skeletal muscle, a mechanism that can be attenuated by EPA.
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A TUMOUR-DERIVED LIPID MOBILISING FACTOR AFFECTS 
CHANGES IN CARBOHYDRATE METABOLISM AND FATTY 
ACID OXIDATION IN CANCER CACHEXIA 
S.T.Russell*
1 and M.J.Tisdale
1.
1 Pharmaceutical Sciences Research Institute, 
Aston University, Aston Triangle, Birmingham, B4 7ET. 
Changes in carbohydrate metabolism are often observed in animals and 
patients with cancer. This may be due to demand from the tumour for a fuel 
source, since solid tumours are anaerobic as a result of poor vascularisation. 
Tumours have previously been shown to utilise glucose with the production 
of lactate with a corresponding up-regulation of the Cori Cycle; which is 
energy depleting and would contribute to the weight loss observed in cancer 
cachexia. 
Previously a tumour-derived lipid mobilising factor (LMF) was isolated from 
the urine of cachectic cancer patients and was shown to produce weight loss 
in non-tumour bearing mice. LMF produced direct lipolysis in isolated 
murine adipocytes suggesting weight loss was specific to loss of adipose 
tissue. LMF was shown to stimulate glucose uptake in C2C12 myoblasts and 
also produced a decrease in serum levels of glucose in vivo. The effect of 
LMF on glucose was examined using the 2-Deoxyglucose tracer method, and 
showed elevated utilisation in the brain, heart, brown adipose tissue (BAT) 
and white adipose tissue (WAT) of non-tumour bearing mice. There were 
also increases observed in the metabolic rates (Rg) of a number of tissues, 
including a 3-fold increase in brain tissue, which may contribute to the 
decrease in glucose serum levels. 
Lipid oxidation was also observed to increase in LMF treated mice, as 
determined by the conversion of 
14C Triolein into 
14CO2. There was a 67% 
increase in oxidation over a 24h period in the LMF treated mice. Lipid 
accumulation was also observed particularly in the liver, WAT and BAT of 
the LMF treated group.  
These results suggest the changes in carbohydrate metabolism and increase in 
whole body fatty acid oxidation observed in cachectic cancer patients may 
arise from the production of LMF. 
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THE INFLUENCE OF NEP/ECE METALLOPROTEINASE 
EXPRESSION ON STROMAL-EPITHELIAL INTERACTIONS IN 
PROSTATE CANCER 
L. A. Dawson*
1, N. J. Maitland
2, A. J. Turner
1, B. A. Usmani
1.
1School of Biochemistry & Molecular Biology, University of Leeds, Leeds 
LS2 9JT; 
2YCR Unit, Dept.of Biology, University of York YO10 5YW 
Prostate cancer (PC) is the most prevalent form of male cancer with one in 
five males currently developing invasive PC. Changes in stromal-epithelial 
interactions in the developing tumour are believed to contribute to PC 
progression and metastasis. A mitogenic role for small regulatory peptides 
including endothelin-1 (ET-1) has been implicated in PC. ET-1 is cleaved 
from its precursor, big ET, through the actions of endothelin-converting-
enzyme (ECE).  Neutral endopeptidase (NEP), which has homology to ECE, 
is known to cleave and inactivate mitogenic peptides such as ET in metastatic 
PC. In previous studies we have shown elevated levels of ECE-1 within the 
stroma adjacent to tumor epithelia in primary prostate adenocarcinomas. In 
this study we propose to investigate the expression of NEP and ECE in 
primary prostatic epithelium, stromal material and in PC cell lines.  This will 
allow elucidation of the role of these peptidases in modulating stromal-
epithelial interactions during PC progression. Matrigel invasion chambers 
will be used to study the effects of normal and malignant stroma on the 
invasive capacity of tumour epithelial cells. The cell lines utilised in this 
study include androgen-sensitive LNCaP, normally transformed PNT-1a, 
PNT2-C2 and P4E6, and androgen-independent PC-3, PPC-1 and Du145 
cells. Preliminary data indicates that stromal cells influence invasion, with 
increased invasion in the presence of stroma. PC-3 cells are highly invasive 
compared to PNT2-C2 cells. The addition of NEP to PC-3 and Du145 cells 
dramatically reduced invasion, with invasive capacity returning to untreated 
levels on addition of NEP inhibitor (phosphoramidon). Further studies are 
being conducted in the presence or absence of ET, ET antagonists, NEP, ECE 
and their inhibitors.  
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NEUTROPHIL-ENDOTHELIAL INTERACTIONS FOLLOWING 
ENDOTHELIAL PRE-CONDITIONING BY THE BREAST 
CARCINOMA CELL LINE, MDA-MB231 
A.C. Brooks
1*, G.B. Nash
2, C.S. Parkins
1, and G.M. Tozer
1.
1Tumour Microcirculation Group, Gray Cancer Institute, Mt Vernon 
Hospital, Northwood, Middx. 
2 Dept. of Physiology, Medical School, 
University of Birmingham 
Neutrophils recruited to sites of inflammation, adhere to endothelial cells and 
evoke vascular injury by undergoing oxidative burst and releasing cytolytic 
granule contents.  It is clear that neutrophil recruitment into tumours plays a 
major role in vascular-targeted therapies
1. Using the endothelial flow cell 
assay, an in vitro model of neutrophil-recruitment under conditions of flow, 
we have previously investigated the effects of the vascular targeting agent 
combretastatin A4-P on neutrophil recruitment.  However, this model 
currently uses endothelial cells isolated from normal tissue, and not tumours.   
Studies using tumour-conditioned endothelial cells in vitro, and in vivo 
studies of tumour vasculature
2, indicate that leukocyte/endothelial-
interactions are decreased in tumours, compared to normal tissue. This 
process termed "tumour anergy", is hypothesized as a mechanism by which 
tumours may evade host immune response.  Here we investigate conditioning 
of normal endothelial cells by the breast carcinoma cell line MDA-MB231, 
and its effects upon neutrophil recruitment in our model system. 
HUVEC were seeded into flow-slides as previously described
3, and placed in 
series with flow-slides containing MDA-MB231 cells and incubated for 
either 24 or 48 hours.  Following conditioning, HUVEC were incubated with 
either vehicle alone or TNF-α  (100 U/ml) for 4 hours prior to neutrophil 
perfusion. Neutrophil recruitment in each category of the adhesive process 
(rolling, firm adhesion, and migration) was recorded. 
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of basal neutrophil recruitment to HUVEC treated with vehicle alone. 
However, a significant decrease in the number firmly adherent, and migrated 
but not rolling neutrophils recruited to TNF-α− activated endothelium was 
observed after 5 minutes of neutrophil perfusion into tumour-conditioned 
slides. This suggests that tumour conditioning affected some factor involved 
in neutrophil firm adhesion, whilst elements involved in rolling remain 
unaffected.  In contrast, following 48 hours of tumour-conditioning both 
basal and TNF-α -activated neutrophil recruitment was significantly 
increased.   
The data presented demonstrate that it is possible to condition normal 
endothelial cells using tumour cells in a modified flow cell assay, and that 
this conditioning is able to modulate neutrophil recruitment.  Further studies 
will examine the factors involved in these alterations in neutrophil 
recruitment. 
1. Cecic I, Parkins CS, Korbelik M (2001): Photochem Photobiol 74: 712-20. 
2. Griffioen AW, Molema G: (2000) Pharmacol Rev 52: 237-68 
3. Luu NT, Rainger GE, Nash GB (1999): J Vasc Res 36: 477-85 
Supported by the Association for International Cancer Research and Cancer 
Research UK 
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PAX3 FUNCTIONS TO PROMOTE SURVIVAL THROUGH 
DOWNREGULATION OF PTEN  
H. Li,* C. J. Parker, and P. Kumar, Biological Sciences Department, 
Manchester Metropolitan University, Chester St., Manchester M1 5GD. 
 The paired box transcription factor PAX3 is expressed in the early embryo in 
neural crest and developing muscle. Its expression has been demonstrated in 
the cell lines and tumour tissues of rhabdomyosarcomas (RMS) and 
melanomas. It has been reported that downregulation of PAX3 can promote 
apoptosis in primary cultures of  melanomas, and PAX3 can upregulate the 
anti-apoptotic protein, BCL-XL in normal and malignant myocytes. PTEN is 
known to modulate PI3 kinase, which is involved in cell survival, migration 
and proliferation. PTEN mutations occur in several tumour types. We have 
constructed a pTet-On doxycycline inducible C2C12 myoblast cell line 
transfected with PAX3 and found that after doxycycline induction of PAX3, 
PTEN was  downregulated. When the C2C12 myoblasts were cultured in 
differentiation medium (2% horse serum in DMEM), doxycycline induction 
of PAX3 expression caused the downregulation of p27. When C2C12 
myoblasts transfected with PAX3 were grown in suspension culture, we 
found using an Annexin V apoptosis staining kit, that the apoptotic index was 
reduced compared with control myoblasts. Cell growth rates were reduced 
(p<0.01) when antisense PAX3 was transfected into an embryonal RMS cell 
line, JR1 and a melanoma cell line, B16F10. These results suggest that PAX3 
may function in survival and proliferation in tumours, partly through 
regulation of the PTEN-PI3K pathway, and may represent a new target for 
cancer treatment.  
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EXPRESSION OF ADAM-11 SPLICE VARIANTS IN BREAST 
CANCER 
C. O￿ Shea*
1, C. Duggan
1, Y. Buggy
2, E. McDermott
2, A.D.K Hill
2, N. O￿ 
Higgins
2, M.J. Duffy
1. Depts. of Nuclear Medicine
1 & Surgery
2, St. Vincent￿s 
University Hospital, Dublin 4, Ireland. 
The ADAMs (A Disintegrin And Metalloprotease) are membrane proteins 
that contain both protease and adhesion domains and thus are potentially 
important in cancer invasion and metastasis. The gene encoding ADAM-11, 
located on chromosome 17q21, has 2 splice variants, i.e., ADAM-11-769 and 
ADAM-11-524. ADAM-11 was reported to be somatically rearranged in 2 
primary breast cancers and was postulated to be a candidate tumour 
suppressor gene. The aim of this study was to investigate the distribution and 
potential clinical significance of ADAM-11 (total) and its splice variants in 
breast cancer. mRNA for total ADAM-11, ADAM-11-769 and ADAM-11-
524 were measured using RT-PCR. The splice variants were separated on 
Spreadex EL 1200 DNA gels. No difference was found in the frequency of 
expression of ADAM-11 (total) or ADAM-11-769 in normal breast tissue 
(n=23), fibroadenomas (n=39), primary breast cancers (n=109) and nodal 
metastases (from breast cancer) (n=8). However, within the ADAM-11 
mRNA-positive tissues, ADAM-11-524 tended to be expressed more often in 
normal breast tissue (5/12, 42%) and fibroadenomas (9/27, 33%) compared to 
the breast cancers (13/70, 19%) and nodal metastases (0/4, 0%). In addition, 
the relative levels of ADAM-11-524 (arbritary units/ADAM-11-769) were 
approximately 4 times higher in normal breast tissue compared to the cancers 
(p=0.0691). Significantly higher levels of ADAM-11 (total) were detected in 
grade 1 and 2 cancers compared to grade 3 tumours (p=0.0393). Moreover, 
expression levels of ADAM-11 (total) in the carcinomas correlated inversely 
with MMP-1 mRNA levels (n=23, r=-0.485, p=0.0228), MMP-2 (active) 
protein levels, as determined by zymography, (n=22, r=-0.564, p=0.0097) 
and uPA protein levels, as determined by ELISA, (n=60, r=-0.349, 
p=0.0074). An inverse relationship was also found between the frequency of 
expression of ADAM-11-524 and uPA mRNA (p=0.004). In conclusion, our 
results show that ADAM-11-524 is expressed less frequently in breast cancer 
than in non-malignant breast tissue. The clinical significance of this 
decreased expression remains to be determined. 
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Survivin is a 16.5 kDa protein that both suppresses apoptosis and regulates 
cell division. Early data suggested that the survivin gene was rarely expressed 
in normal tissue, but was widely expressed in malignancy. These findings 
suggested that survivin might be a new candidate marker for breast cancer. 
The aim of this investigation was to compare the expression of survivin in 
benign and malignant breast tissue. Survivin expression was measured at the 
protein level using both ELISA and Western blotting and at the mRNA level 
using RT-PCR. Using ELISA, higher levels of survivin protein were detected 
in both primary breast carcinomas (n=70) and nodal metastases (from breast 
cancer) (n=16) compared with fibroadenomas (n=16) (p=0.0069, p=0.0131, 
respectively). Using Western blotting, survivin protein was detected in a 
higher proportion of nodal metastases (19/19, 100%) and carcinomas (69/77, 
90%) than fibroadenomas (18/26,69%) (p=0.0226, p=0.0300, respectively). 
Similarly, survivin mRNA levels were significantly higher in the cancers 
compared to the fibroadenomas (p=0.0001). In addition, frequency of 
expression of survivin protein, as measured by Western blotting, tended to be 
higher in mRNA-positive tumours (24/25, 96%) than mRNA-negative 
cancers (2/4, 50%) (p=0.0515). Expression levels of survivin protein in the 
carcinomas, as determined by ELISA, correlated positively with tumor grade 
(n=61, r=0.432, p=0.0007) and inversely with estrogen receptor (n=63, r=-
0.316, p=0.0121) and progesterone receptor (n=64, r=-0.380, p=0.0028) 
concentrations. Higher levels of survivin protein were also found in ductal 
carcinomas compared to lobular cancers (p=0.0424) However, no significant 
relationship was found between survivin protein and either axillary nodal 
involvement or tumor size. We conclude that while survivin is detected in the 
majority of carcinomas, it is also present in benign breast tissue. Further work 
is necessary to establish a possible clinical value for survivin in breast cancer.  
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INVOLVEMENT OF TIP60 IN ANDROGEN RECEPTOR 
SIGNALLING 
Vasileia Sapountzi*, Ian R. Logan, David E. Neal, Craig N. Robson 
Prostate Research Group, School of Surgical Sciences, Medical School, 
University of Newcastle Upon Tyne, Newcastle Upon Tyne, NE2 4HH, 
United Kingdom 
Prostate cancer is one of the most common causes of death for males in 
Western countries. In the initial stages of the disease, carcinoma is essentially 
curable and exhibits androgen dependent growth. In the later stages of the 
disease however, it can develop androgen independence that often results in 
death. Androgen receptor mediated signalling pathways are critical in normal 
prostate development and play an important role in the progression of 
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androgens but also by hormone independent phosphorylation through various 
kinase pathways. AR mediates its effect on gene expression with the aid of 
coregulatory molecules. One AR coactivator is TIP60, a protein initially 
found to interact with the Tat protein of HIV-1(1, 2). Several coactivators are 
at least partially regulated by phosphorylation. 
In this study, growth factor signalling pathways including the fibroblast 
growth factor (FGF) and the epidermal growth factor (EGF), and pathways 
involving protein kinase A (PKA), protein kinase C (PKC), mitogen activated 
protein kinases (MAPK) and Ca
2+- dependent kinases (CaMK) were screened 
to see if they affect TIP60 transcriptional activity. We demonstrate that PKA 
affects TIP60 transcriptional activity, as shown by mammalian one-hybrid 
assays and this effect is diminished by dominant negative PKA suggesting 
that the effect of PKA on TIP60 is dependent on the catalytic activity of 
PKA. This is of particular interest as PKA has been shown to activate AR 
through phosphorylation (3). Finally, EGF, but not FGF1 or FGF2, appears to 
alter TIP60 activity. These results, in combination with previous findings that 
protein kinase pathways activate AR, highlight the importance of TIP60 in 
AR mediated transactivation and implicate phosphorylation as an important 
mechanism in androgen independent activation of AR signalling. 
1.Kamine, J., Elangovan, B., Subramanian, T., Coleman, D. & Chinnadurai, 
G. (1996) Virology 216, 357-66. 
2.Brady, M. E., Ozanne, D. M., Gaughan, L., Waite, I., Cook, S., Neal, D. E. 
& Robson, C. N. (1999) J Biol Chem 274, 17599-604. 
3.Nazareth, L. V. & Weigel, N. L. (1996) J Biol Chem 271, 19900-7. 
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Introduction and Objectives: The genes for the prodrug converting enzyme 
E. Coli Nitroreductase (NR) and the reporter gene enhanced Green 
Fluorescent Protein (eGFP) have been cloned into adenoviral gene therapy 
vectors. The transgenes are controlled by a double PSA enhancer & single 
PSA promoter transcriptional regulatory region (TRR) termed ￿PSAeep￿. 
The activity of this promoter was investigated in prostate cancer cell lines as 
well as primary prostate tissue. The stability of this PSA TRR was examined 
by Southern blotting. Methods: The human cell lines LNCaP, PC-3 and 
DU145, and the mouse prostate cancer cell lines TRAMP C1 and C2 were 
infected with adenovirus containing the reporter transgene eGFP and 
expression assessed by UV microscopy and FACS analysis. Thin sections of 
cultured primary prostate tissue from radical prostatectomy specimens were 
infected with adenovirus, and transgene expression analysed. Apoptosis 
induced by the combination of nitroreductase expressing adenovirus and 
CB1954 was visualised with the cytokeratin 18 antibody M30. Southern 
blotting of restriction enzyme digests of adenoviral DNA was performed to 
assess stability of the TRR.  Results: GFP expression was detected in all 
human but not the TRAMP cell lines on UV microscopy and FACS analysis. 
Gene expression levels in the cell lines PC-3 & DU145 were lower than in 
LNCaP from the PSAeep TRR. Primary prostate tissue infections confirmed 
eGFP expression exclusively from glandular epithelium. Apoptosis was also 
confined to glandular epithelium with NR expressing adenovirus and 
CB1954. Southern blotting of viral DNA digests showed instability of this 
PSA TRR, with evidence of recombination to form single and triple enhancer 
variants during viral replication. Conclusions: Epithelial specificity of the 
PSA promoter-enhancer construct was confirmed in primary prostate tissue. 
Genetic instability with evidence of homologous recombination was found in 
viral DNA, making this vector unsuitable for clinical trials. Novel methods to 
increase the strength of PSA TRR driven gene therapy will have to be found 
as replication of promoter or enhancer elements leads to genetic instability in 
vectors.  
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DISULFIRAM INHIBITS 5-FU-INDUCED NF-κκκκ B ACTIVITY AND 
ENHANCES CYTOTOXICITY OF 5-FU TO HUMAN COLORECTAL 
CANCER CELL LINES 
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Colorectal cancer (CRC) is the third leading cause of cancer deaths in 
developed nations. 5-fluorouracil (5-FU) is the first line agent for CRC 
chemotherapy. Resistance of cancer cells to 5-FU induced apoptosis is 
considered the major mechanism of chemoresistance leading to the failure of 
CRC chemotherapy. NF-κ B is an anti-apoptotic transcription factor. Cancer 
cells with high NF-κ B nuclear activity demonstrate robust chemo- and 
radioresistance. Disulfiram (DS) is an anti-alcoholism drug inhibiting TNFα
induced NF-κ B activity in T lymphocytes. The aim of this study is to 
investigate the influence of DS on NF-κ B activity in CRC cell lines and 
effect of DS on the cytotoxicity of 5-FU to these cell lines. The nuclear NF-
κ B activity in CRC cell lines DLD-1 and RKOwt was significantly induced 
by 5-FU treatment in a concentration- and time-dependent manner. NF-κ B
subunits p50 and p65 were involved in 5-FU-induced NF-κ B activity. 
Compared to drug-sensitive cells, Thymidylate synthase inhibitors (5-FU and 
Tomudex) resistant cell lines (H6305FU, H630TDX, RKOTDX, W1L2TDX and 
R105FU) demonstrated higher constitutive NF-κ B nuclear activity. The protein 
and mRNA of NF-κ B p50 and p65 subunits were overexpressed in these cell 
lines but no DNA amplification was detected. 5-FU induced Iκ Bα
degradation, promoted NF-κ B nuclear translocation but not its DNA binding 
affinity. 5-FU treatment did not influence the activities of AP-1, AP-2, Oct-1, 
SP-1, CRE-B and TFIID. DS strongly inhibited constitutive and 5-FU-
induced NF-κ B activity in a dose-dependent manner. DS inhibited both NF-
κ B nuclear translocation and DNA binding affinity but has no effect on 5-
FU-induced Iκ Bα  degradation. Used in combination, DS significantly 
enhanced the apoptotic effect of 5-FU on DLD-1 and RKOwt cell lines and 
synergistically potentiated the cytotoxicity of 5-FU to both cell lines. As well, 
DS can reverse the resistance of H6305FU cells to 5-FU. As an authorised anti-
alcoholism drug, the pre-clinical and clinical data of DS are available. It is 
relatively simple to translate its anticancer usage from in vitro experiment to 
clinical trial.  
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SERIAL MOLECULAR ANALYSIS OF BCR-ABL EXPRESSION 
AND CHIMERISM STATUS IN CML PATIENTS FOLLOWING 
STI571 TREATMENT.   
Gately K.
*, Ryan J., McCann S., Howard J., Stallings R., Carroll P., Browne 
P, Conneally E,  Lawler M. Department of Haematology St James’s Hospital 
and Trinity College Dublin; National Centre for Medical Genetics, Our 
Lady’s Hospital for Sick Children, Crumlin, Dublin, Ireland  
Chronic Myelogenous Leukemia (CML) is a stem cell malignancy which is 
characterised by the disease specific marker, the Philadelphia chromosome. 
This is a result of the translocation t(9;22) which generates the bcr-abl fusion 
gene encoding a leukemia specific tyrosine kinase p210. Enhanced tyrosine 
kinase activity by p210 contributes to the abnormal intracellular signalling, 
defective adhesion and resistance to apoptosis characteristic of CML cells. 
STI 571 is a tyrosine kinase inhibitor which has been proven effective in the 
treatment of CML. Serial molecular analysis is being performed in 35 
patients receiving STI571(Novartis) at St James￿s Hospital. Peripheral blood 
and bone marrow are collected from patients prior to STI treatment and at 
regular intervals during treatment. Lineage selection is performed on all 
samples to isolate populations of CD34
+, CD33
+ and CD15
+ cells using 
magnetic bead selection. Molecular studies have been designed to measure 
changes in bcr-abl expression (as a marker of STI571￿s efficiency as an anti 
leukemia drug). A quantitative real time  RT-PCR assay has been developed 
to detect bcr-abl and has a sensitivity of detection of 1 leukaemia cell in a 
background of 10
6 normal cells. Real time RT-PCR analysis indicates   
substantial downregulation of bcr-abl mRNA at 6 months in patients with 
haematological and cytogenetic responses (n = 17 ). Four patients in the study 
had relapsed following allogeneic stem cell transplantation (SCT). Two 
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patients, a partial response was seen following immunotherapy using donor 
lymphocyte infusions (DLI) from the original donor. Both of these  patients 
relapsed and subsequently received a non myeloablative stem cell transplant. 
In both patients a partial response was seen but the patients subsequently 
relapsed and received STI 571. All 4 patients are currently being monitored 
both by quantitative RT-PCR of bcr-abl and chimerism analysis to ascertain 
the origin of hemopoesis (donor or recipient) using short tandem repeat PCR 
of monoclonal antibody selected haemopoetic lineages. In the 2 patients who 
received STI 571 following relapse after allogeneic SCT,  serial analyses of 
chimerism and bcr-abl positivity have shown reversion to donor chimerism 
in all lineages  and bcr-abl negativity following treatment with STI.  The 3rd 
patient showed a partial response with reduction in bcr-abl transcripts and 
70% donor chimerism while in the 4th patient there was no significant 
reduction in bcr-abl transcripts and chimerism analysis indicated 20-30% 
donor cells in all lineages tested.  Thus STI treatment leads to a significant 
reduction in bcr-abl transcripts in CML patients in chronic phase  although 
no patient has achieved complete bcr-abl negativity. In patients receiving 
STI-571 following relapse after allogeneic SCT, molecular analysis using 
both real time PCR and chimerism analysis indicates that complete clearance 
of bcr-abl transcripts and reversion to donor hemopoiesis can be achieved. 
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GLYCINE-EXTENDED GASTRIN STIMULATION OF MMP-2 
SECRETION  IN DIFFERENT CELL TYPES IS NOT SPECIFIC TO 
ONE ISOFORM OF THE CCK-2 RECEPTOR 
RA Dean*, PA Clarke, SA Watson 
Academic Unit of Cancer Studies, QMC, University Hospital, Nottingham, 
NG7 2UH 
Background & Aims: Gastrin has growth promoting effects on both normal 
and malignant tissues of the gastrointestinal tract. The cholecystokinin/gastrin 
receptor (CCK-2R) can occur in several isoforms, which may have roles to 
play in a gastrin autocrine pathway in malignant cells. Glycine-extended 
gastrin (Gly-G17) has been shown to promote matrix metalloproteinase 
(MMP) secretion and therefore we are investigating whether the CCK-2 
isoforms have different effects on MMP secretion. 
Methods: Gelatin zymography was used to investigate the protein expression 
of MMP-2 in eight cell lines with or without the stimulation of GlyG17 (10
-
7M). Western blotting was used to characterise which type of CCK-2R 
isoform each cell line expressed, using antibodies specific for either the 
classical or truncated CCK-2 receptor. The cell lines investigated were the 
human fibrosarcoma HT1080 transfected with MT1-MMP, the mouse 
fibroblast NIH 3T3 line transfected with the classical CCK-2 or truncated 
CCK-2 receptor, and the human gastro-intestinal tumour cell line AGS 
transfected with classical CCK-2R, as well as all their respective vector 
control cell lines. 
Results: A significant increase in pro and active MMP-2 (p<0.05) and 
proMMP-9 (p<0.05) at the protein level, following stimulation by GlyG17 
was observed in the human fibrosarcoma cell line transfected with MT1-
MMP. This transfected cell line had a 2.7 fold increase in the expression of a 
~98kDa band when blotted for classical CCK-2R, compared to its vector 
control. The truncated CCK-2 receptor NIH 3T3 transfectants had a 
significant increase (p<0.05) in proMMP-2 and expressed a ~68kDa band 
when blotted for the truncated CCK-2R. Neither of the two classical CCK-2R 
transfectants, (AGS and 3T3) showed a significant change in MMP-2 
secretion. 
Conclusion: GlyG17 has previously been shown to increase protein levels of 
pro and active MMP-2 in a human colonic cancer cell line. We have shown 
that this stimulation by GlyG17 is mediated through either  classical or 
truncated CCK-2R although presence of receptor does not confirm the effect. 
Further research needs to be undertaken to determine the  mechanism by 
which Gly-G17 can increase MMP-2 secretion and or activation. 
P182 
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Aims 
Targeted radiotherapy is the selective irradiation of tumour cells by 
radionuclides conjugated to tumour-seeking molecules. The most promising 
non-immunological agent is radiolabelled MIBG which is actively taken up 
via the noradrenaline transporter (NAT) in a narrow range of NAT expressing 
tumours. To apply MIBG targeting for a wider range of tumours, we 
introduced NAT cDNA into non-NAT expressing UVW glioma cells and 
achieved high levels of  [1
31I]MIBG uptake and dose-dependent cell kill.  
Cell kill has been demonstrated in three-dimensional tumour spheroids, 
which succumb to [
131I] MIBG mediated cell kill more readily than 
monolayers due to the radiation cross-fire, which is an added benefit of this 
strategy. To assess the magnitude of radiation mediated bystander effects, we 
have developed an in vitro tumour model, transfected mosaic spheroids 
(TMS), which allow modelling of gene therapy strategies when less than 
100% of the spheroid express the therapeutic transgene. 
Methods 
TMS are spheroids composed of two cell populations derived from a single 
parent cell line.  One population of cells are transfected with NAT, the other 
with GFP as a marker for non-transfection.  Spheroids composed of various 
proportions of NAT expressing cells were prepared by mixing the correct 
proportions of the two cell populations in a spheroid spinner flask. TMS were 
then dosed with of [
131I]MIBG and [
211At]MABG and cytotoxicity 
determined by clonogenic assay and spheroid regrowth delay. 
Results 
Cell killing in TMS by [
131I]MIBG and [
211At]MABG, increased in direct 
proportion to the fraction of NAT-transfected cells and dose administered. 
When only 5% 0f the cells within the spheroid expressed NAT, the spheroids 
were sterilised after administration of 14MBq/ml [
131I]MIBG.  [
211At]MABG 
was 700X more radiotoxic with spheroid sterilisation occurring after 
administration of only 20kBq/ml [
211At]MABG. 
Conclusions 
No current gene delivery tool allows introduction of transgenes to every cell 
within a tumour. Cancer gene therapy strategies must therefore have a 
component of collateral cell kill.  We developed a TMS model to allow 
quantification of bystander effect and utilised it to demonstrate the efficacy of 
a novel targeted radiotherapy/gene therapy strategy utilising astatinated 
MABG, which allows spheroid sterilisation when only 5% of the tumour 
mass expresses NAT. This level of gene transfection should be readily 
attainable in vivo and suggests that this system may be effective for the 
treatment of cancer. 
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VINORELBINE INDUCES p38 BUT NOT MAPK ACTIVATION NOR 
p53 EXPRESSION IN BREAST CANCER CELL LINES 
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Background To overcome the problem of drug resistance in breast cancer 
treatment, combination chemotherapy is administered. The combination of 
vinorelbine and doxorubicin in the treatment of metastatic breast cancer 
patients has shown higher overall response rates and even vinorelbine as a 
single agent in patients previously exposed to anthracyclines has resulted in a 
significant remissions. This could be due to mechanisms involved in the 
multidrug resistance phenomenon. Alterations in signal transduction and 
mutant p53 are thought to play a role in drug resistance. Cross-talk has been 
suggested between these signal transduction pathways and p53. To establish 
the effect of doxorubicin and vinorelbine upon signal transduction and p53,
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performed using MDA-MB-468 and MCF-7 breast cancer cell lines.  
Materials and Methods Using the IC50 value for vinorelbine and 
doxorubicin, MDA-MB-468 and MCF-7 were treated for a total of 4 hours. 
While maintaining the Vinorelbine treatment for 3 hours, doxorubicin was 
added either 1 hour before (pretreatment doxorubicin), 1 hour after 
(pretreatment vinorelbine), or at the same time (combined). Single agent 
controls were set up during pre- and combined treatment. p38 and MAPK 
activity was determined  by kinase assay for the appropriate substrate. p53 
expression was determined by western blotting in MCF-7 cells following 
treatment for 4 and 24 hrs with both drugs using the IC30 values as single 
agent or in combination.  
Results   A higher activity of p38 following vinorelbine-based, but not 
doxorubicin-based, treatment was demonstrated in both cell lines. This higher 
activation was noted irrespective of whether vinorelbine was given as a 
pretreatment or simultaneously with doxorubicin. MAPK activity and p53
expression remained unchanged following vinorelbine treatment.
Conclusion  Higher p38 activity has been linked previously to p53 
phosphorylation, resulting in apoptosis or cell cycle arrest. Our findings, 
however, suggest a model where p38 activity and p53 expression function 
independently in response to chemotherapy treatment in breast cancer. 
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Microcell-mediated transfer of chromosome 11 to a clonal derivative of 
ovarian cancer cell line OVCAR3 produced microcell hybrids which display 
suppression of growth and cellular migration in vitro and inhibition of tumour 
growth in vivo.
Subsequently, mRNA populations from OHN, a clonal derivative of the 
OVCAR3 parent line, and from 11OH2.1, a growth suppressed microcell 
hybrid, were used for expression difference analysis by Differential Display 
RT-PCR (DDRT-PCR), cDNA-Representational Difference Analysis 
(cDNA-RDA) and cDNA high density filter array (HDFA). These techniques 
identified genes both up and down regulated with respect to growth.  
Quantitative real time RT-PCR was used to validate all expression 
differences in X transcripts. We identified, in total, 12 validated products 
upregulated in suppressed clone 11OH2.1 and 4 validated products that were 
downregulated. 
The genes downregulated in association with growth suppression, and 
therefore of potentially oncogenic function, were RALDH2, IGFBP2 and 2 
novel cDNAs. When examined on cell line and primary tumour panels, these 
genes did not however appear to demonstrate a global increase in expression 
over normal ovarian expression. 
Of the 12 genes upregulated in association with growth suppression, 4 were 
localised on chromosome 11. These were cathepsin D, proteasome subunit 
PSMD13, ribosomal subunit RPL27a and α B crystallin. All were shown to 
have decreased expression in several of the cell lines and primary tumours 
tested.  Furthermore, a tight correlation was observed between the expression 
of PSMD13 and RPL27a in cell lines and primary ovarian tumours. The 
significance of this association is being investigated. It is clear that the 
coupling of functional and expression difference analysis approaches can 
identify contextually important gene expression underlying cancer 
phenotypes. 
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MOLECULAR MECHANISMS OF CD40-INDUCED CELL 
SURVIVAL IN PRIMARY MALIGNANT B-CELLS 
Claire Dallman*, Peter WM Johnson and Graham Packham,  
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of Southampton, Southampton General Hospital, Southampton, SO16 6YD, 
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Introduction: CD40 is a potent survival signalling molecule for normal B-
cells and some B-cell malignancies. Activation of CD40 promotes 
proliferation, B-cell activation and rescue from apoptosis. However, in some 
cellular settings CD40 ligation induces growth arrest and apoptosis. CD40 
stimulation regulates the expression of apoptosis controlling molecules, 
including A20, Survivin and the Bcl-2 family members, Bcl-XL, Mcl-1 and 
Bfl-1. However, few studies have analysed the expression of these CD40 
targets in primary lymphoid cells.  
Methods: Following ethical approval (Southampton & S. West Hants LREC 
Submission 158/00), malignant B-cells were isolated from lymph nodes, 
spleens or blood samples using density centrifugation and immunomagnetic 
depletion of non B-cells. We studied low and intermediate grade lymphomas 
and chronic lymphocytic leukaemias. B-cell purity was determined by flow 
cytometry. The response of isolated B-cells to CD40 stimulation was 
determined by treatment with soluble recombinant CD40 ligand (CD40L). 
Cell viability was determined by propidium iodide exclusion. Isolated B-cells 
were cultured with and without CD40L for up to 72 hrs.  Expression of 
apoptosis regulators was analysed by immunoblotting and semi-quantitative 
RT-PCR.  There are multiple Bcl-X promoters and their relative activity was 
measured using specific primers. 
Results:  CD40L suppressed apoptosis in all B-cell malignancies tested, 
accompanied by significant increases in Bcl-XL protein expression.  Bcl-X 
promoters were differentially regulated by CD40. Mcl-1 protein expression 
was also increased or maintained by CD40 stimulation, independent of 
changes in Mcl-1 RNA levels.  Although Survivin, A20, Bfl-1 and Bnip3 
were regulated by CD40 in some samples, this was not consistent. 
Conclusions : CD40 ligation promotes cell survival in all primary B-cell 
malignancies studied to date.  The anti-apoptotic proteins , Bcl-XL and Mcl-1 
are consistently regulated by CD40 whereas other molecules, suggested to be 
important from studies of cell lines, are only regulated in a subset of samples. 
Further work will involve analysing more samples and normal B-cell controls 
and determining the contribution of Bcl-XL and Mcl-1 using antisense 
approaches.  The mechanisms by which CD40 regulates the Bcl-X promoters 
will be an area of further research and may help to identify targets for the 
treatment of B-cell malignancies. 
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CASPASE DEPENDENT CLEAVAGE OF THE ANTI-APOPTOTIC 
MCL-1 PROTEIN 
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Introduction: Mcl-1 is a member of the Bcl-2 family with predominantly 
anti-apoptotic functions. It is down regulated in many cell systems early 
during apoptosis which may be important for effective cell killing. This down 
regulation is often in contrast to other anti-apoptotic family members like 
Bcl-2 and Bcl-XL. Overexpression of Mcl-1 can increase the apoptotic 
threshold to various cytotoxic insults. Transgenic mice overexpressing Mcl-1 
develop lymphoma with a high frequency.  Here we have investigated 
mechanisms that control the expression of Mcl-1 protein during apoptosis.   
Methods: Cell lines were treated with cytotoxic agents in the presence or 
absence of the caspase inhibitor ZVAD-fmk. Mcl-1 expression was 
determined by immunoblotting and   induction of apoptosis was confirmed by 
analysis of PARP cleavage, a caspase target.  To determine susceptibility to 
in vitro caspase cleavage human Mcl-1, Bcl-2 and Bcl-XL proteins were 
generated by in vitro translation and incubated with recombinant caspase 3.  
Mcl-1 cleavage sites were determined by sequencing of caspase 3-derived 
cleavage products and these sites were mutated by introduction of an 
Asp>Ala substitution.  The susceptibility of wild type and mutant Mcl-1 
proteins to in vitro caspase 3 mediated cleavage was determined. 
Results: Mcl-1 expression was down regulated during apoptosis in several 
cell systems, concomitant with PARP cleavage.  Down regulation is caspase 
dependent since it was prevented by ZVAD-fmk.  Mcl-1 is cleaved 
efficiently in vitro by caspase 3, whereas Bcl-2 and Bcl-XL are not.  Caspase 
3 cleavage sites were mapped to Asp127 and Asp157; mutation of these sites 
Poster Presentations
S90
British Journal of Cancer (2002) 86(Suppl 1), S34–S121 ã 2002 Cancer Research UKprevented caspase cleavage. These cleavage sites are evolutionary conserved 
in mouse, rat and zebra fish. 
Conclusions: Our data confirm that Mcl-1 is down regulated in various cell 
systems in a caspase dependent manner during apoptosis. We have 
determined two caspase 3 cleavage sites within Mcl-1 and Mcl-1 is therefore 
likely to be a direct substrate for caspase cleavage in vivo. We are presently 
investigating if caspase resistant Mcl-1 mutations can alter the apoptotic 
response of cells to cytotoxic stimuli and if caspase cleavage of Mcl-1 is the 
main mechanism of down regulation of Mcl-1 during apoptosis. 
P187 
BAG-1 PREVENTS STRESS-INDUCED APOPTOSIS AND LONG 
TERM GROWTH INHIBITION IN BREAST CANCER CELLS VIA 
AN HSC70/HSP70-DEPENDENT PATHWAY 
Graham Packham*, Ramsey Cutress, Paul Townsend 
CRC Wessex Medical Oncology Unit, Cancer Sciences Division, School of 
Medicine, University of Southampton, Southampton General Hospital, 
Southampton, SO16 6YD 
Introduction.  BAG-1 is a survival protein that interacts with a wide range of 
cellular targets.  Although there is strong evidence that increased expression 
of BAG-1 may play an important role in breast cancer, the function of BAG-
1 in breast cancer cells has not been studied in detail. 
Procedures.  We overexpressed BAG-1 in MCF7 breast cancer cells to 
determine its effects on apoptosis and proliferation.  We used BAG-1 mutants 
to identify key amino-acid residues required for BAG-1 function.  
Results.  BAG-1 overexpression completely protected MCF7 cells from 
apoptosis and long term growth inhibition induced by heat shock.  BAG-1 
overexpression also partially protected cells from other cell stresses, 
including hypoxia, radiation and chemotoxic drugs.  BAG-1 function 
required a conserved lysine in the BAG-1 N-terminal ubiquitin-like domain, 
thought to be important for interaction with the proteasome.  BAG-1 function 
was also dependent on C-terminus residues important for interaction with 70 
kDa heat shock protein, HSC70 and HSP70. 
Conclusions.  BAG-1 overexpression confers a broad resistance to stress in 
breast cancer cells.  BAG-1 may function by linking chaperone molecules 
with the proteasome, to regulate or facilitate protein degradation. 
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FUNCTIONAL COMPLEMENTATION ANALYSIS OF 
CHROMOSOME 1 IN NEUROBLASTOMA 
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Introduction:  Neuroblastoma (NB) is the most common extracranial solid 
tumour of infancy and the third most frequent malignant tumour in children 
accounting for 15% of all childhood cancer deaths.  Chromosome 1p 
deletions and MYCN gene amplification in NB are common genetic 
abnormalities and correlate with a poor prognosis.  1p deletions are found in 
approximately 30% to 40% of primary NB cases while MYCN amplification 
is seen in 20% to 30% of cases.  Deletion mapping studies and somatic cell 
fusion experiments suggest that multiple tumour suppressor genes (TSG) 
located on 1p are involved in NB development and possibly control MYCN
expression.  To date, no specific TSG has been identified to be lost or 
inactivated in NB, nor has a causal link between 1p loss and the malignant 
phenotype been established. 
Methods: Functional complementation analysis for the presence of a TSG(s) 
that plays a role in NB was conducted using microcell mediated chromosome 
transfer (MMCT).  Microcells were generated from mouse hybrid cell lines 
that carry either a whole human chromosome 1 tagged with the hygromycin 
resistance gene or a fragment (1p36-1q23) tagged with the neomycin 
resistance gene (located at 1p35-1p34).  Microcells were fused with IMR-32 
neuroblastoma cells that have a 1p deleted and MYCN amplified status.   
Resistant hybrids were selected.  A panel of informative chromosome 1 
microsatellite markers determined the extent of chromosome 1 incorporated 
into the hybrids.   
Results: Fourteen hygromycin resistant IMR-32 hybrids were generated, four 
of which show marked differentiation in vitro.  A further hybrid that failed to 
grow indefinitely exhibited a particularly extreme degree of neurofilament 
development.  All the established hybrids carried material from 1q and 
proximal 1p regions but none acquired additional material from distal 1p 
regions.  PCR for the hygromycin resistance gene and FISH analysis using 
chromosome 1 paint and chromosome 1 centromeric marker were performed 
t o  f u r t h e r  c o n f i r m  t h e  t r a n s f e r  o f  c h r o m o s o m e  1 .    F u s i o n  o f  m i c r o c e l l s  
carrying the 1p36-1q23 fragment with IMR-32 cells did not generate any 
viable hybrids. 
Conclusion: These results are consistent with the hypothesis that normal 1p 
is not compatible with the genetic background of cells carrying MYCN
amplification.  The map of the transferred chromosome 1 regions indicates 
selection against the incorporation of distal 1p regions into IMR-32 cells.  
Moreover, the morphology of the hybrids suggests that one or more regions 
on chromosome 1 may influence differentiation of NB.  More detailed 
mapping studies will reveal whether a particular region of chromosome 1 is 
associated with the differentiation. 
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ANALYSIS OF BRCA1 AND BRCA2 GENES IN THE IRISH 
POULATION USING DENATURING HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY (dHPLC). 
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Children, Crumlin, Dublin 12, Ireland and University College Dublin, Dept. 
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Hospital, Dublin.  4.
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Mutation analysis of disease related human genes requires highly sensitive, 
specific and reproducible tecniques.  Many of the techniques currently in use 
are time consuming and laborious.  The recent development of denaturing 
high performance liquid chromatography (dHPLC), which is based on 
heteroduplex detection promises to fulfill these requirements.  This technique 
exploits the differential retention time of homoduplex and heteroduplex 
fragments on an alkylated non-porous matrix under conditions of partial heat 
denaturation.  This allows for the automated detection of single nucleotide 
polymorphisms and small deletions or insertions. 
Since the identification of the BRCA1 and BRCA2 genes >500 sequence 
variants have been detected world-wide.  Approximately 60-70% were 
truncating mutations and the remainder were polymorphisms or missense 
mutations.  It is clear for complete analysis of BRCA1 and BRCA2 that the 
protein truncation test (PTT) is not sufficient, as missense mutations do not 
alter the protein size and therefore cannot be analysed by PTT.  As both 
genes are large, (21 and 27 exons respectively), with exon 11 in both genes 
accounting for almost 60% of coding regions, sequencing of the coding and 
flanking regions would be time consuming and expensive.  The alternative 
method of dHPLC was chosen to produce a comprehensive analysis of 
BRCA1 and BRCA2 sequence variants in breast/ovarian cancer patients in 
the Irish population.   
We have identified 2 BCRA1 mutations, 1294del40 and E143X, which 
appear to be common in the Irish population.  Currently we have analyzed 25 
exons from BRCA2 and 21 exons from BRCA1 in 116 patients, from a larger 
cohort of approximately 230 patients.  Analysis is ongoing, but to date we 
have identified 85 BRCA2 sequence variants in 58 patients. Some of these 
appear to be common polymorphisms in the Irish population, others are non-
conservative mutations or mutations of unkown effect. 
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AP-1 AS A MEDIATOR OF ANDROGEN REFRACTORY PROSTATE  
CANCER  
*N Sarath Krishna
￿, J Edwards
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￿, K M Grigor
￿ & J M S 
Bartlett
￿
￿University Department of Surgery & Urology, Glasgow Royal Infirmary & 
￿Western General Hospital, Edinburgh. 
Introduction-Hormonal therapy remains the treatment of choice for 
metastatic  prostate cancer. However development of androgen refractory 
state is a serious clinical problem, for which there is currently no effective 
therapy. AP-1 is a complex of transcription factors c-Jun & c-fos, activated 
by Protein Kinase C. These proteins are up regulated in prostate cancer cell 
lines in the absence of androgens & there is a strong evidence that PKC 
activity is required for the survival and growth of androgen independent 
human prostate cancer cells. In-vivo studies are yet to be carried out. We 
propose to investigate this using human prostate cancer tissue.  
Aims-1.To investigate the levels of expression of c-Jun, c-fos & AR proteins 
in paired pre & post cancer tissue from prostate cancer patients who have 
developed androgen refractory state. 
2.To identify patients in whose tumours up regulation of AP-1 may be 
mediating androgen refractory state. 
Methods-Forty-one patients with prostate cancer who have progressed to 
androgen refractory state were identified retrospectively from their clinical 
records. Their pre & post androgen refractory prostate tumour tissue [41 
paired samples] provided material for study. Phosphorylated c-Jun, c-fos, AR 
& PSA levels of expression were quantified by immunohistochemistry.   
Results-PSA was expressed in all the tissue samples tested indicating 
activation of androgen regulated genes. Increased expression of c-Jun/c-fos 
was observed in 32% [13/41] of post androgen refractory prostate cancer 
samples when compared with pre androgen refractory values. AR expression 
remained unaltered or decreased in 56% [23/41] of post androgen refractory 
prostate cancer biopsies when compared to the matched pre androgen 
refractory tissue. AR expression was increased in 44%. No significant 
difference in c-Jun/fos expression was observed in tumours with increased 
AR vs no change in AR expression. 
Conclusion-We have demonstrated up-regulation and activation (via 
phosphorylation of c-Jun) of the AP-1 transcription factor in a significant 
subset [32%] of patients who have progressed to androgen refractory prostate 
cancer, independent of changes in AR expression. In this subset of patients, 
AP-1 may have a dominant effect in cancer progression via activation of 
androgen regulated genes by an AR independent mechanism. AP-1 could be 
a potential target for future therapies against androgen refractory prostate 
cancer in a selected group of patients. 
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ALTERATIONS IN MITOCHONDRIA AND MITOCHONDRIAL 
DNA-ENCODED ENZYMES IN RAT BLADDER TUMORS INDUCED 
BY BBN 
∗ Guang-fu Chen
1, Franky L Chan
2, Peter SF Chan
1
Departments of Surgery1 and Anatomy2, Prince of Wales Hospital, Chinese 
University of Hong Kong, Hong Kong 
Objectives 
This study investigated the ultrastructural changes in mitochondria and 
changes in the mitochondrial DNA-encoded enzymes of oxidative 
phosphorylation in bladder cancer induced by BBN [N-butyl-N-(4-
hydroxybutyl) nitrosamine] in rats. 
Methods 
A total of 180 male SD rats were given drinking water containing 0.05% 
BBN at libitum for 4 to 28 weeks. Control rats were given tap water without 
BBN. The normal bladder and tumor were processed for electron and light 
microscopy, and immunohistochemistry for mitochondrial enzymes of 
oxidative phosphorylation such as cytochrome c oxidase subunit II (COX II), 
cytochrome c, ubiquinol cytochrome c oxidoreductase, cytochrome c oxidase 
and ATP synthase. Protein expressions of mitochondrial enzymes were 
analyzed by Western blotting using the same antibodies for 
immunohistochemistry. The mRNA expression of mitochondrial enzymes 
was also analyzed by RT-PCR and Northern blotting. For RT-PCR analyses, 
normal and hyperplastic transitional epithelia were removed by laser capture 
microdissection. 
Results 
Both transitional cell carcinoma and squamous cell carcinoma were induced 
in the rat bladder after treatment with BBN for 16 to 28 weeks. Our results 
demonstrated a significant increase in the number of mitochondria in the 
BBN-induced carcinogenesis. Analyses of protein expressions of 
mitochondrial enzymes showed that these mitochondrial enzymes were 
increased in the BBN-induced bladder carcinomas. Similar increase in their 
mRNA expression levels was detected by RT-PCR. Northern blot analysis of 
COX II using a 218-bp RNA probe also showed a similar increase in mRNA 
levels of this enzyme.   
Conclusions 
Our study showed that there was significant increase in the number of 
mitochondria, and significant increases in both protein and mRNA expression 
of mitochondrial enzymes of oxidative phosphorylation in BBN-induced 
hyperplastic bladder epithelia and carcinomas as compared to normal bladder 
epithelium. These observations suggest that mitochondria and mitochondrial 
DNA-encoded enzymes might play an important role in BBN-induced rat 
bladder carcinogenesis. 
P192 
FUNCTIONAL ANALYSIS OF THE RASSF1A TUMOUR 
SUPPRESSOR GENE  USING YEAST TWO-HYBRID SCREEN 
S.L.Fenton*, L.B.Hesson, A.Agathanggelou, E.R. Maher, F Latif. 
Dept of Medical and Molecular Genetics, Medical School, University of 
Birmingham, B15-2TT. 
We and others have shown that multiple tumour suppressor genes may reside 
on chromosome 3p and that their inactivation plays a role in the pathogenesis 
of a number of common cancers including breast and lung. One newly 
identified gene located at 3p21.3 is the tumour suppressor gene RASSF1A. 
Previously, we demonstrated that inactivation of RASSF1A by allelic loss 
and methylation is a critical step in the development of a number of cancer 
types including breast, lung, neuroblastoma, and kidney tumours. The 
characterisation of proteins encoded by tumour suppressor genes such as 
RASSF1A, their binding partners and their location is crucial to 
understanding the function of a protein and its role in tumour development.  
A yeast two-hybrid screen was performed in order to look for novel 
RASSF1A binding partners using MATCHMAKER system 3 
(CLONTECH). The bait vector PGBKT7-RASSF1A (56-871bp) was 
constructed and transformed in yeast strain S. cerevisiae AH109 (MATa). 
The bait RASSF1A-BD was then used to screen a pretransformed 
MATCHMAKER brain library cloned in pACT2 and introduced into yeast 
strain S.cerevisiae Y187 (MATa). A total of 6 x 10
6 clones were screened, of 
which 103 were positive for α -galactosidase expression. Clones were rescued 
and retransformed into yeast to reconfirm positive interactions. Positive 
clones were sequenced. From the above screen we identified ten independent 
clones, which encode for known genes involved in transcription regulation, 
cell division and cell signalling. In addition we also identified five novel 
genes in our screen of RASSF1A binding proteins.  
We are now in the process of confirming all of our interacting clones in vitro
using coimmunoprecipitation and GST fusion pull downs. The full length 
cDNAs of the interacting proteins and deletion constructs will also be studied 
using these techniques to identify interacting regions. We will then go on to 
verify these interactions in vivo in their native environments using 
mammalian MATCHMAKER Two-hybrid using the pCMV-Myc and 
pCMV-HA vectors and by transfecting into mammalian cell lines in order to 
observe the effects of in vivo expression on RASSF1A signalling. Clinically, 
this is extremely important because we need to establish the function of 
tumour suppressor genes such as RASSF1A if we are to restore normal gene 
function 
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RNA POLYMERASE III TRANSCRIPTION CAN BE DEREPRESSED 
BY ONCOGENES OR MUTATIONS THAT COMPROMISE p53 
FUNCTION IN TUMOURS AND LI-FRAUMENI SYNDROME 
Torsten Stein1, Diane Crighton1*, Jennifer Morton1, John M. Boyle2, 
Jennifer M. Varley2 and Robert J. White1 
1Institute of Biomedical and Life Sciences, Division of Biochemistry and 
Molecular Biology, Davidson Building, University of Glasgow, Glasgow, 
G12 8QQ, U.K. 
2Cancer Research Campaign Department of Cancer Genetics, Paterson 
Institute for Cancer Research, Wilmslow Road, Manchester, M20 9BX, U.K. 
 
RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA 
and 5S rRNA.  Wild-type p53 can repress pol III transcription both in vitro 
and in vivo (1-2).  Many tumours carry substitutions in p53 which have 
selective effects on its functions.  We identify tumour-derived mutations that 
compromise the ability of p53 to regulate pol III transcription (3).   
Furthermore, substitution R175H, the most common mutation in cancers, 
converts p53 from a repressor to an activator of pol III.  Human 
papillomavirus E6 and cellular hdm2 can both release pol III from repression 
by p53.  These data suggest that the restraining influence of p53 on pol III 
will be lost in many tumours.  In addition to these features of sporadic 
cancers, some individuals inherit mutant forms of p53 and consequently 
suffer from Li-Fraumeni syndrome, showing genetic predisposition to certain 
malignancies.  We find that pol III transcriptional activity is often highly 
elevated in primary fibroblasts from Li-Fraumeni patients, especially if the 
germline p53 mutation is followed by loss of the remaining allele.  Our data 
suggest that p53 status can have a profound effect upon pol III transcription 
and hence on the biosynthetic capacity of cells.   
1.  Chesnokov, I., Chu, W.-M., Botchan, M. R. and Schmid, C. W. (1996) 
Mol Cell Biol 16, 7084.  
2.  Cairns, C. A. and White, R. J. (1998) EMBO J. 17, 3112.  
3. Stein, T., Crighton, D., Boyle, J. M., Varley, J. M. and White, R. J. (2002) 
Oncogene In press.  
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Arginine vasopressin (AVP) is a neuropeptide that is expressed in small cell 
lung cancer (SCLC) but not in non small cell lung cancer (NSCLC). On the 
over expression of the transcription factors Upstream Stimulatory Factor 1 
and/ or 2 (USF-1 and USF-2), the vasopressin promoter can be activated and 
studied in NSCLC. Here we investigate the motif through which these 
transcription factors activate. 
Methods: PCR mediated site-directed mutagenesis was carried out within the 
promoter region to generate mutations at three sites, the C-Ebox, E-Motif and 
the TATAbox. The fragments were initially cloned into the pCR2.1 vector 
then subcloned into chloramphenicol acetyl transferase (CAT) reporter 
constructs. Electroporation was used as a transfection method to introduce the 
reporter constructs into NCI-H460, a NSCLC cell line. Co-transfection was 
with a Beta-Galactosidase reporter gene construct to standardise the 
individual experiments. Reporter gene assays were used to measure the level 
of promoter activity. 
Results: The mutations were generated within two different sized fragments: 
(-52 to +42) and (-52 to +56), the larger promoter fragments also included a 
mutated D-Ebox. The assays showed the same pattern of activity for the two 
sets of promoter constructs when cotransfected with the USF-2 transcription 
factor. The effect of USF-1 on the constructs (-52 to +42) was similar to that 
of USF-2 but at a reduced level. The mutations at the C-Ebox had no effect 
on promoter activity. In contrast mutations at the E-Motif and those with 
double mutations at both the E-Motif and C-Ebox abolished activity of the 
promoter. Mutations at the TATAbox also resulted in minimal activity of the 
promoter. 
Discussion: The E-Motif and the TATAbox were both required for activation 
of the vasopressin promoter in NSCLC. However it was clear that the E-
Motif is the promoter site through which USF activation of AVP is mediated 
in lung cancer. 
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Recent experimental evidence indicates that chronic immune activation, 
associated with angiogenesis, suppression of cell mediated immunity and 
inhibition of apoptosis, plays a central role in the development of malignant 
disease.  Malignant mesothelioma (MM) represents a pleural tumour which 
fits this model.  Crocidolite fibres are intimately associated with the 
development of MM.  These fibres have been demonstrated to upregulate 
epidermal growth factor receptor (EGFR) expression and to induce cell 
signalling events, including activation of the phosphotidylinositol-3-
kinase/Akt and MAP-kinase pathways in human mesothelial cells.  Following 
inhalation, carcinogenic asbestos fibres also induce the release of a number of 
cytokines from pulmonary macrophages including tumour necrosis factor   
(TNF)-.  We examined the effects of TNF- exposure on simian virus-40 
immortalised human mesothelial Met5A cells.  TNF- induced upregulation 
and phosphorylation of the EGFR.  This was blocked by pre-treatment with 
N-acetyl-cysteine indicating that the effects were due to oxidative stress.   
Using gel mobility shift assays TNF- increased transcription factor NF-B 
binding to DNA, an effect partially blocked by pre-treatment with the 
selective EGFR tyrosine kinase inhibitor PKI166.  TNF- exposure was 
associated with increased cell proliferation, an effect completely abrogated 
by exposure to the NF-B decoy peptide SN50.  Gene microarray analysis 
revealed upregulation of a range of genes within the Met5A cells including 
the apoptosis inhibitors CIAP1 and 2 and FLIP and the pro-angiogenic 
cytokines IL-6 and IL-8 implicated in the suppression of cell mediated 
immune responses.  These results indicate that TNF- induces EGFR cell 
signalling events which contribute to the activation of NF-B by the 
cytokine.  Activation of NF-B appears crucial to TNF- induced cell 
proliferation.  Furthermore TNF- exposure results in the upregulation of 
genes capable of inducing a local chronic immune activation state which 
would favour the survival and subsequent mutation of stress induced 
transformed pre-malignant cells.  The findings suggest that TNF- plays a 
central role in MM tumourigenesis. 
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INTERLEUKIN-8 (IL-8) PROMOTES AUTOCRINE GROWTH OF 
PROSTATE CANCER CELLS 
Maryalice Hamill*, Johanna Messenger, Monica Monaghan, Jayne Draffin, 
Patrick Johnston and David Waugh 
Department of Oncology, Queen’s University Belfast, Belfast City Hospital, 
Belfast, BT9 7AB 
 
Prostate cancer is currently the most prevalent cancer in men and the second 
leading cause of cancer-related deaths in males. Over-expression of the 
chemokine IL-8 has been reported in the sera of patients with localized and 
metastatic cancer of the prostate. Animal models have also positively 
correlated the expression of IL-8 with the tumorigenicity and metastasis of 
prostate cancer. However, the underlying mechanism by which IL-8 appears 
to promote disease progression remains poorly understood. Since IL-8 has 
been proposed to act as an autocrine growth factor in melanoma and colon 
cancer, we initiated a study to determine the effect of IL-8 upon the growth of 
two prostate cell lines, the metastatic PC3 cell line and the transformed 
PNT1A epithelial cell line. IL-8 administration produced a consistent, 
concentration-dependent increase in PC3 cell growth as assessed by cell 
count analysis. The response had an apparent EC50 of 1nM and produced a 
mean increase of 45% in cell number when compared to untreated cells. The 
PNT1A cell line demonstrated negligible response to exogenous IL-8. 
Expression of the IL-8 receptors, CXCR1 and CXCR2, was detectable in 
both cell lines using RT-PCR. Therefore, further analysis of receptor 
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